Financial Justifications for the Software-as-a-Service Business Model Trend Based on Financial Differences between Companies in the Software-as-a-Service and Pharmaceutical Industry
Abstract
The Software-as-a-Service (SaaS) business model is a new type of business model that has
gained great attention from both researchers and practitioners. The rapid growth has resulted
in a more and more refined business model and is described as the future of software. Thus, it
is not unexpected that the model is frequently used for many start-ups. The business model
relies on the so-called SaaS pricing model, i.e. services that are often provided and developed
continuously and paid recurrently. This is in contrast to the more traditional industries, such
as the pharmaceutical (pharma), who are supplying pharmaceutical drugs used for
medication, where many of the large multinational corporations originate from the 19th
century. The pharma business model is characterized by its substantial initial project
investments, long project and product life cycles with lump-sum payments.
The purpose of this report is to assess the justifications of the SaaS business model trend, by
comparing the financial differences between the SaaS and pharma industries. The aim is to
identify differences between capital structure, profitability, and cash flow to embrace an
understanding of the financial implications of the business models. In order to ease financial
decision-making regarding business models, in both academia as well as the business sector.
The methodology was based on a deductive research design, that was executed through an
external and objective approach with emphasis on a quantitative collection and analysis of
data. The collected data was based on a sample of 20 companies, with 10 in the SaaS industry
and 10 in the pharma industry, for the time period 2015-2019. The analysis was conducted
through unpaired t-test for the variables capital structure, free cash flow in relation to both
revenue and operating, and profitability in the sense of return on assets and profit margin.
The findings indicate that there are weak justifications for the SaaS business model trend
from a financial perspective, in terms of capital structure, cash flow and profitability. Thus, if
these are of high importance other more traditional business models should be considered. On
the other hand, there are other justifications for the SaaS business model trend, as the
business model embraces scaling, low initial and marginal costs, recurrent payments, and
continuous development during deployment.
Degree
Student essay
View/ Open
Date
2021-02-24Author
Lindvall, Johannes
Olsson, Daniel
Keywords
Software-as-a-Service, Pharmaceutical, Financial differences
Series/Report no.
Industriell och finansiell ekonomi
20/21:5
Language
eng